Glycotope GmbH | MedPath

CHMP Recommends ENHERTU® Approval for HER2 Low/Ultralow Metastatic Breast Cancer in EU

3 months ago

• The European Medicines Agency's CHMP has recommended approval of ENHERTU® for patients with HER2 low or ultralow metastatic breast cancer who have received prior endocrine therapy. • This regulatory milestone expands treatment options for metastatic breast cancer patients with lower HER2 expression levels, addressing an important unmet medical need. • The recommendation follows successful clinical trials demonstrating ENHERTU's efficacy in this patient population, marking a significant advancement in targeted breast cancer therapy.